GYOEDU

EORTC 55971

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

Date of Publication:

September 2, 2010

Pubmed Link:

https://pubmed.ncbi.nlm.nih.gov/20818904/

Hypothesis:

Is neoadjuvant chemotherapy followed by interval debulking surgery non-inferior to primary debulking surgery in advanced stage ovarian cancer?

Control Arm(s):

Primary debulking surgeryat least 6 cycles platinum based chemotherapy

Experimental Arm(s):

3 cycles platinum based chemotherapyinterval debulking surgery (if response or stable)at least 3 additional cycles of platinum based chemotherapy

Primary End Point:

OS (non-inferiority design)

Inclusion Criteria:

stage IIIC or IV epithelial ovarian cancer

Exclusion Criteria:

contraindication to PDS or NACT

Results:

PDS (n=336) vs NACT/IDS (n=334):≤1cm residual disease: 41.6% vs 80.6%Grade 5 complications: 2.5% vs 0.7% (comparison not performed)median PFS: 12 vs 12 months (NS)median OS: 29 vs 30 months (NS)

Conclusions:

NACT/IDS is not inferior to PDS for advanced stage ovarian cancer patient

Reviewer:

Olga T Filippova